Abstract

The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence-based medicine, healthcare resource availability, and precision medicine. These updates address the differences in epidemiological characteristics, clinicopathological features, tumor biology, treatment patterns, and drug selections between Eastern and Western gastric cancer patients. Key revisions include a structured template for imaging diagnosis reports, updated standards for molecular marker testing in pathological diagnosis, and an elevated recommendation for neoadjuvant chemotherapy in stage III gastric cancer. For advanced metastatic gastric cancer, the guidelines introduce new recommendations for immunotherapy, anti-angiogenic therapy and targeted drugs, along with updated management strategies for human epidermal growth factor receptor 2 (HER2)-positive and deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) patients. Additionally, the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric cancer. The 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice, particularly in the heterogeneous healthcare landscape of China, while maintaining a commitment to scientific rigor, impartiality, and timely revisions.

Details

Title
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
Author
Feng-Hua, Wang 1   VIAFID ORCID Logo  ; Xiao-Tian, Zhang 2 ; Tang, Lei 3 ; Wu, Qi 4 ; Mu-Yan, Cai 5   VIAFID ORCID Logo  ; Yuan-Fang, Li 6   VIAFID ORCID Logo  ; Xiu-Juan Qu 7 ; Qiu, Hong 8 ; Yu-Jing, Zhang 9 ; Jie-Er Ying 10   VIAFID ORCID Logo  ; Zhang, Jun 11   VIAFID ORCID Logo  ; Ling-Yu, Sun 12 ; Rong-Bo, Lin 13   VIAFID ORCID Logo  ; Wang, Chang 14   VIAFID ORCID Logo  ; Liu, Hao 15 ; Miao-Zhen Qiu 1   VIAFID ORCID Logo  ; Wen-Long, Guan 1 ; Sheng-Xiang, Rao 16 ; Jia-Fu, Ji 17 ; Yan, Xin 18 ; Wei-Qi, Sheng 19 ; Hui-Mian, Xu 20   VIAFID ORCID Logo  ; Zhi-Wei, Zhou 21 ; Ai-Ping, Zhou 22 ; Jin, Jing 23 ; Xiang-Lin, Yuan 24 ; Bi, Feng 25   VIAFID ORCID Logo  ; Tian-Shu, Liu 26 ; Han, Liang 27   VIAFID ORCID Logo  ; Yan-Qiao, Zhang 28 ; Guo-Xin, Li 15 ; Liang, Jun 29 ; Bao-Rui, Liu 30 ; Shen, Lin 31   VIAFID ORCID Logo  ; Li, Jin 32 ; Rui-Hua, Xu 1   VIAFID ORCID Logo 

1  Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China 
2  Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, P. R. China 
3  Department of Radiology, Peking University Cancer Hospital, Beijing, P. R. China 
4  Department of Endoscopy Center, Peking University Cancer Hospital, Beijing, P. R. China 
5  Department of Pathology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, P. R. China 
6  Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China 
7  Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China 
8  Department of Medical Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China 
9  Department of Radiotherapy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China 
10  Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China 
11  Department of Medical Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P. R. China 
12  Department of Surgical Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P. R. China 
13  Department of Medical Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, P. R. China 
14  Tumor Center, The First Hospital of Jilin University, Changchun, Jilin, P. R. China 
15  Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China 
16  Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China 
17  Department of Gastrointestinal Surgery, Peking University Cancer Hospital, Beijing, P. R. China 
18  Pathology Laboratory of Gastrointestinal Tumor, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China 
19  Department of Pathology, Zhongshan Hospital Affiliated to Shanghai Fudan University, Shanghai, P. R. China 
20  Department of Gastrointestinal Oncology Surgery. The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China 
21  Department of Gastric Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, P. R. China 
22  Department of Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China 
23  Department of Radiation Oncology, Shenzhen hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, P. R. China 
24  Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China 
25  Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China 
26  Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, P. R. China 
27  Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, Tianjin, P. R. China 
28  Department of Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, P. R. China 
29  Department of Medical Oncology, Peking University International Hospital, Beijing, P. R. China 
30  Department of Medical Oncology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, P. R. China 
31  Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, P. R. China 
32  Department of Oncology, Easter Hospital affiliated to Shanghai Tongji University, Shanghai, P. R. China 
Pages
127-172
Section
GUIDELINES
Publication year
2024
Publication date
Jan 2024
Publisher
John Wiley & Sons, Inc.
e-ISSN
2523-3548
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1002/cac2.12516
ProQuest document ID
2915665658
Copyright
© 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.